Abstract: A formulation including a material that is in a wet-state in which the material is an uncured concrete, an uncured cementitious material, or a combination thereof, a Quat Silane that cures on and/or within the material, a fungicide, and a defoamer.

Abstract: An additive formulation for reduction or prevention of microbially induced corrosion in concrete, cementitious material (such as mortar or grout), or a combination thereof. The additive formulation comprises a Quat Silane and a fungicide, wherein the ratio of the Quat Silane to the fungicide in the formulation is in a range of about 10:1 to about 1:10, preferably in a range of about 5:1 to about 1:5.

Abstract: Disclosed are methods of forming a chamber component for a process chamber. The methods may include filling a mold with nanoparticles or plasma spraying nanoparticles, where at least a portion of the nanoparticles include a core particle and a thin film coating over the core particle. The core particle and thin film are formed of, independently, a rare earth metal-containing oxide, a rare earth metal-containing fluoride, a rare earth metal-containing oxyfluoride, or combinations thereof. The nanoparticles may have a donut-shape having a spherical form with indentations on opposite sides. The methods also may include sintering the nanoparticles to form the chamber component and materials. Further described are chamber components and coatings formed from the described nanoparticles.

Abstract: Embodiments disclosed herein provide an organic matter processing apparatus and method for the use thereof to convert organic matter into a ground and desiccated product. This can be accomplished using a bucket assembly that can grind, paddle, and heat organic matter contained therein. An algorithm is used to control the conversion of organic input to organic output by progressing through processing states based, in part, on time windows, runtimes, and sensor inputs.

Abstract: Animal waste contains most of the essential nutrients required for plant growth. However, animal waste also contains microbes that convert urea to ammonium ions, nitrification of the ammonium ions to NO2 and NO3 and denitrification of NO2 or NO3 to N2. N2O is produced as an intermediate of nitrification and denitrification processes and N2O is a 300 times more potent greenhouse gas than CO2. The instant invention discloses low-cost, fluid suspension compositions comprising a combination of urease, nitrification and denitrification inhibitors that decrease the loss of nitrogen from animal waste and lessen the biological formation of the greenhouse gas N2O. These compositions comprise nitrogenous phosphoryl compounds and nitrification inhibitors that utilize manufacturing processes for the formation of low cost, fluid suspensions comprising one or more inhibitor particles selected from the group consisting of urease inhibitor particles, b) nitrification inhibitor particles, and c) fused particles.

Abstract: A solid rocket propellant includes a hydroxyl-terminated polybudadiene (HTPB) binder system having a high molecular weight diol that is greater than thirty carbon atoms (>C30) and less than fifty carbon atoms (<C50) and excluding dimeryl diisocyanate (DDI).

Abstract: The invention relates to a process, catalysts, materials for conversion of renewable electricity, air, and water to low or zero carbon fuels and chemicals by the direct capture of carbon dioxide from the atmosphere and the conversion of the carbon dioxide to fuels and chemicals using hydrogen produced by the electrolysis of water.

Abstract: A method for chemically reducing carbon dioxide (CO2) with a red mud catalyst composition is provided includes introducing a gaseous mixture of CO2 and H2 into a reactor containing particles of the red mud catalyst composition. The method further includes reacting at least a portion of the CO2 and H2 in the gaseous mixture in the presence of the red mud catalyst composition at a temperature of 200 to 800° C., and under a pressure ranging from 5 to 100 bar to form a gaseous product including a chemical reduction product of the CO2. A volume ratio of the CO2 to the H2 in the gaseous mixture is in a range of 1:10 to 10:1.

Abstract: A method for chemically reducing carbon dioxide (CO2) with a red mud catalyst composition is provided includes introducing a gaseous mixture of CO2 and H2 into a reactor containing particles of the red mud catalyst composition. The method further includes reacting at least a portion of the CO2 and H2 in the gaseous mixture in the presence of the red mud catalyst composition at a temperature of 200 to 800° C., and under a pressure ranging from 5 to 100 bar to form a gaseous product including a chemical reduction product of the CO2. A volume ratio of the CO2 to the H2 in the gaseous mixture is in a range of 1:10 to 10:1.

Abstract: A fluidized apparatus contains a double-trapezoid structural member. These fluidized apparatuses are used in the nitro compound hydrogenation reaction process. The fluidized apparatus includes a shell, a gas distributor, and an inner chamber defined by an inner wall of said shell and an upper surface of said gas distributor, in the middle region of said inner chamber is disposed a perforated plate, the perforated plate comprise an outer edge region and a center region, assuming the opening rate of the outer edge region is A1 (the unit is %), assuming the opening rate of the center region is A2 (the unit is %), then A1/A2=0-0.95.

Abstract: In one aspect, the disclosure relates to methods for preparation of terpene and terpene-like molecules. In a further aspect, the disclosure relates to the products of the disclosed methods, i.e., terpene and terpene-like molecules prepared using the disclosed methods. Intermediates for the synthesis of a wide variety of terpenoids are ?-allyl Knoevenagel adducts or quasi ?-allyl Knoevenagel adducts are disclosed. In various aspects, methods of preparing terpenoids through these intermediates are disclosed. The methods can comprise ?-alkylation of an allylic electrophile followed by ring-closure metathesis to a polycyclic terpenoid structure. In a further aspect, the disclosure pertains to terpenoid frameworks, and compounds prepared via disclosed oxidation and substitution reactions on the disclosed terpenoid frameworks. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: Described herein are crystalline forms of a prostacyclin (IP) receptor agonist compound, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist compound.

Abstract: This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to Heat Shock Transcription Factor 1 (HSF1) activity and/or function. More particularly, this disclosure relates to methods of inhibiting HSF1 activity with these compounds and pharmaceutical compositions thereof, and methods of treating diseases associated with HSF1 activity and/or function, such as cancer.

Abstract: The invention provides a compound of formula I and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the formula I compounds, as well as methods of using such as therapeutic agents for the treatment of pain-related disorders and diseases and in combination with other therapeutic agents.

Abstract: Disclosed by the present invention are an SIRT6 small-molecule allosteric activator and the application thereof and provided is an SIRT6 small-molecule allosteric activator that contains a derivative as shown in formula (1) or a pharmacologically acceptable salt thereof as the active ingredient. The SIRT6 small-molecule allosteric activator designed and synthesized in the present invention has high efficacy and low toxicity, may significantly activate SIRT6 activity during in vitro experiments, and has great importance in the development of pharmaceuticals for relevant diseases.

Abstract: The present disclosure is directed to novel derivatives of naturally occurring humulones and lupulones, methods of making them, compositions comprising them, and methods for using them.

Abstract: A method for producing one or more of benzene, toluene, or xylene may include contacting a feed stream including C9+ alkylaromatic hydrocarbons with a catalyst mixture to form one or more of benzene, toluene, or xylene. The catalyst mixture may include mesoporous zeolite Beta, ZSM-5 zeolite, one or more active metals, and binder material. The feed stream may include C9+ alkylaromatic hydrocarbons in an amount of at least 10 wt. %. The weight ratio of mesoporous zeolite Beta to ZSM-5 zeolite may be from 2 to 4.

Abstract: A system and method for producing acetic acid, including dry reforming methane with carbon dioxide to give syngas, cryogenically separating carbon monoxide from the syngas giving a first stream including primarily carbon monoxide and a second stream including carbon monoxide and hydrogen. The method includes synthesizing methanol from the second stream via hydrogenation of carbon monoxide in the second stream, synthesizing dimethyl ether from the methanol, and generating acetic acid from the dimethyl ether and first-stream carbon monoxide.

Abstract: The invention relates to the purification of an acrylic acid comprising aldehyde compounds in a low content, according to a distillation process in a distillation unit in the absence of chemical reagent for treating the aldehydes, producing a stream of polymer-grade acrylic acid which is withdrawn through a side outlet of the distillation unit. The invention makes it possible to eliminate the use of a product classified as CMR in the manufacture of polymer-grade acrylic acid from a technical-grade acrylic acid, and thus meets the HSE requirements for industrial plants.

Abstract: A method for preparing methyl acrylate comprises: a) heating in a reaction zone a mixture comprising acrylic acid, methanol, and an acid catalyst to react and form a reaction product comprising methyl acrylate which is vaporized with other light components and then fed to a distillation zone, wherein a feed stream entering the reaction zone comprises methanol to acrylic acid in a molar ratio of greater than 1 and less than 2, and a residence time in the reaction zone ranges from 0.25 to 2 hours; b) condensing and phase-separating a distillate from the distillation zone to form an organic phase comprising methyl acrylate and an aqueous phase; c) returning a portion of the organic phase to the distillation zone as organic reflux; and d) feeding the remainder of the organic phase and the aqueous phase of the distillation zone to an extraction column to form a methanol rich aqueous effluent and an organic effluent comprising methyl acrylate.

Abstract: The invention relates to a process wherein a dialkyl carbonate stream containing an ether alkanol impurity is subjected to extractive distillation using an extraction solvent to obtain a top stream comprising dialkyl carbonate and a bottom stream comprising the ether alkanol impurity and the extraction solvent, wherein the extraction solvent is an organic compound containing one or more ester moieties and/or ether moieties which organic compound does not contain a hydroxyl group. Further, the invention relates to a process for making a diaryl carbonate, comprising reacting an aryl alcohol with a stream containing a dialkyl carbonate from which stream an ether alkanol impurity has been removed in accordance with the above-described process.

Abstract: Described herein is an iron(II)-phthalocyanine catalyzed C—H bond amination of alkyl azides. The catalyst is effective to produce intramolecular amination of saturated C—H bonds in moderate to excellent yields and the methods are tolerant of a wide scope of substrates. The methods described are useful for the synthesis of natural products derivatives and for the late-stage functionalization of pharmaceuticals.

Abstract: Provided are a salt form of an estrogen receptor down-regulator, a crystalline form thereof, and a preparation method therefor

Abstract: A compound represented by the following formula (1): wherein in the formula (1), a ring XB is a six-membered hydrocarbon ring or a six-membered heterocyclic ring having one or two nitrogen atoms; one or more sets of adjacent two of XB1 to XB4 are fused with a substituted or unsubstituted hydrocarbon ring including 5 to 50 ring carbon atoms, or a substituted or unsubstituted heterocyclic ring including 5 to 50 ring atoms; one or more sets of adjacent two of XC1 to XC3 are fused with a substituted or unsubstituted hydrocarbon ring including 5 to 50 ring carbon atoms or a substituted or unsubstituted heterocyclic ring including 5 to 50 ring atoms.

Abstract: To provide a novel therapeutic agent for fibrosis that induces selective cell death of lung fibroblasts and suppresses lung fibrosis without injuring alvocar epithelial cells. A pharmaceutical composition for treating fibrosis, the pharmaceutical composition comprising a compound of formula (I) or formula (II): wherein in formula (I), R1 represents a C1-4 alkyl group optionally substituted with a halogen atom, and l represents an integer of 3 to 6; and in formula (II), n represents an integer of 8 to 12, or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt thereof.

Abstract: Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.

Abstract: Disclosed herein are adiponectin receptor agonists and methods of using the same for the treatment of inflammation or bone loss in a subject.

Abstract: The present invention relates to methods for synthesizing compounds, and to intermediates thereto, useful for treating various conditions in which aldehyde toxicity is implicated in the pathogenesis.

Abstract: Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

Abstract: A novel benzoheterocycle compound or a pharmaceutically acceptable salt thereof showed a high anti-proliferative effect against cancer cell lines. Using this, a pharmaceutical composition for preventing or treating cancer disease can comprise the compound or a pharmaceutically acceptable salt thereof as an active ingredient. In addition, a health functional food composition for preventing or improving cancer disease can include the compound or a pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition or health functional food composition can effectively prevent or treat various cancer diseases.

Abstract: Aldoketo reductase (AKR) inhibitors having formulas I-III are used to treat disorders associated with NO/SNO deficiency.

Abstract: The present invention provides for novel co-crystals of lenalidomide. The present invention particularly provides for novel cocrystals of lenalidomide with Resorcinol, Methyl paraben and Saccharin. The present invention also provides for the processes for the production of cocrystals of lenalidomide with Resorcinol, Methyl paraben and Saccharin. The present invention further provides for processes for the preparation of crystalline anhydrous lenalidomide Form IV.

Abstract: The present invention provides an industrially advantageous production method of (1R,2S)-2-{[((2,4-dimethylpyrimidin-5-yl)oxy}methyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide. (1R,2S)-2-{[((2,4-Dimethylpyrimidin-5-yl)oxy}methyl]-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide (compound [A]) is produced by an industrially advantageous method by a route via a novel compound. wherein each symbol is as described in the description.

Abstract: Disclosed herein are compounds of the formula: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. The compounds and compositions provided herein may be used for the treatment or prevention of diseases or disorders, including but not limited to cancer (e.g., pancreatic cancer), including drug-resistant cancers, such as gemcitabine-resistant pancreatic cancer or KRAS dependent tumors.

Abstract: Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of certain chemokine receptor activity.

Abstract: The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

Abstract: The present disclosure provides compounds of Formula I, Ia, Ib, Ib-1, Ib-2, Ic, Ic-1, Id-1, and Id-2. Compounds of Formula I, Ia, Ib, Ib-1, Ib-2, Ic, Ic-1, Id-1, and Id-2 may be used in pharmaceutical formulations, and may be used for modulating glucocorticoid receptors.

Abstract: The invention provides novel benzamides of pyrazolyl-amino-pyrimidinyl derivatives of Formula (I) as selective and potent JAK inhibitors for treating various diseases and disorders. The invention also provides pharmaceutical composition of these compounds and methods of their preparation and use thereof.

Abstract: An organic molecule is disclosed having: one first chemical moiety with a structure of Formula I, and three second chemical moieties, each independently from another with a structure of Formula II, wherein the first chemical moiety is linked to each of the three second chemical moieties via a single bond.

Abstract: Provided are piperazine substituted fused azadecalin compounds of Formula J, I, Ia, Ib, Ib-1, Ib-2, Ic and Id for use in pharmaceutical formulations, and for modulating glucocorticoid receptors.

Abstract: Described herein are oxazole TRPML1 agonists and pharmaceutical compositions comprising said agonists. The subject compounds and compositions are useful for the treatment of TRPML1-mediated disorders or diseases.

Abstract: The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.

Abstract: Disclosed is a compound, a complex comprising same, an anti-cancer pharmaceutical composition, and an anti-cancer drug. The compound can have the structure represented by chemical formula 1.

Abstract: The present invention relates to compounds that are Nrf2 activators. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with Nrf2 activation.

Abstract: Provided herein is a bulk composition comprising the trihydrate form of (3S, 4R, 3?R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methoxy-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3?-yl ester di-hydrochloride salt. Provided are also pharmaceutical compositions and dosage forms comprising the trihydrate form, and methods and uses for treating a gastrointestinal disorder in a subject with the trihydrate form. In some embodiments, the gastrointestinal disorder is gastroesophageal reflux disease (GERD), dyspepsia (such as functional dyspepsia or functional motility disorder), gastroparesis, paralytic ileus, post-operative ileus, emesis, nausea, heartburn, intestinal pseudo-obstruction, irritable bowel syndrome (IBS), constipation, enteral feeding intolerance (EFI), or esophagitis. In some embodiments, the gastrointestinal disorder is post-operative ileus, chronic grass sickness, constipation, megacolon, gastritis, gastrointestinal stasis, or abomasal emptying defect.

Abstract: There is provided the crystal of a heterocyclic amide compound and a method for producing the same wherein the heterocyclic amide compound defined as a compound having useful activity as herbicide contains a novel crystal, as shown in formula (1):

Abstract: The present invention provides a compound having antiviral activity, especially having arenavirus proliferation inhibitory activity, and/or a medicament comprising the compound. More preferably, the present invention provides a compound having proliferation inhibitory activity on the Old World arenaviruses such as Luna virus, Lassa virus, and lymphocytic choriomeningitis virus and/or the New World arenaviruses such as Junin virus, and/or a medicament comprising the compound.

Abstract: Polycystic ovary syndrome (PCOS) is characterized by elevated levels of androgens, cysts in the ovaries, and irregular periods. Women with PCOS present with additional symptoms, including hirsutism, alopecia, acne, infertility, weight gain, fatigue, depression and mood changes. The present disclosure provides new compounds, salts, compositions and uses thereof in the treatment of PCOS due to elevated adrenal androgens. Further, the present disclosure provides methods for treating PCOS due to elevated adrenal androgens.

Abstract: Disclosed herein are compounds that can prevent and treat C. difficile by inhibiting sporulation. Also disclosed herein are compositions and formulations comprising the compound disclosed herein. Methods of preventing and treating C. difficile comprising administering the compounds described herein are also disclosed.

Abstract: The present invention provides novel compounds of Formula (I), (II), or (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, ovarian cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g.